What Womed does

Womed SAS is a privately held French medical device company headquartered in Montpellier that develops intrauterine therapies for women's uterine health conditions. The company was spun off in 2018 from research conducted at the University of Montpellier's biopolymer lab and operates on a patented tri-block copolymer platform (composed of PLA and PEO) that enables easy insertion through the cervix and tunable degradability for intrauterine drug delivery. Its flagship commercial product, Womed Leaf, is a soft 0.02-inch resorbable polymer film that self-deploys inside the uterine cavity, acts as a mechanical barrier for approximately one week following hysteroscopic surgery, and then naturally dissolves and is discharged without intervention. Womed Leaf received CE marking in 2021 and FDA Premarket Approval in 2024, supported by the PREG1 first-in-human study and the PREG2 pivotal RCT (160 patients, 16 sites, 7 countries plus China), which demonstrated a 2.4x higher probability of avoiding adhesion recurrence versus no prevention.

Womed is commercializing Womed Leaf for the prevention of intrauterine adhesions (Asherman syndrome) following hysteroscopic adhesiolysis, addressing a recurrence problem affecting up to 62.5% of severe cases. The company distributes through KARL STORZ (exclusive U.S. distributor as of March 2026), KEBOMED (France, Germany, Nordic countries, Austria, Switzerland), and Saesco Medical (Spain, Italy, Portugal, BeNeLux), with direct hospital sales and Hyperpharma online pharmacy fulfillment in additional EU markets. The platform supports a four-product pipeline: Womed Leaf (marketed), Eynia for uterine fibroids (Phase II, using selective progesterone receptor modulators), an acute uterine bleeding treatment for emergency settings, and an endometriosis therapy, with pipeline programs co-funded by the European Innovation Council. The company is led by Chairman Gonzague Issenmann (former STENTYS CEO, INSEAD MBA) alongside clinical and scientific co-founders Stephanie Huberlant, MD/PhD and Xavier Garric, PhD.

Womed generates revenue through one-time hardware sales of its medical devices to healthcare providers and (in the EU) through pharmacies, with pricing not publicly disclosed. The company has raised approximately $6.6 million in disclosed venture funding (IRDI SORIDEC Gestion-led round in December 2023) plus undisclosed EIC Accelerator support (February 2024), and is currently raising additional capital via Lita and Capital Cell equity crowdfunding platforms to accelerate U.S. commercialization and pipeline advancement. The company holds ISO 13485 certification and reports more than 3,000 patients treated globally across 16 EU countries, the United States, and Brazil.

Name

Womed

Legal name

WOMED SAS

Website

https://womedtech.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Womed SAS is a Montpellier-based medical device company commercializing Womed Leaf, the first FDA-approved resorbable intrauterine adhesion barrier for Asherman syndrome, and developing a pipeline of intrauterine drug delivery therapies for fibroids, endometriosis, and acute uterine bleeding using its patented tri-block copolymer platform.

Ownership category

akta.pro rank

Product category

Women's Health Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Single-Use Medical Disposables & Procedure Kits (Drapes, Tubing, Catheters, Syringes, Custom Packs) (HLAHANAG)

akta.pro secondary industry

Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN)

Keywords

• Intrauterine medical devices
• Resorbable adhesion barriers
• Gynecological medical devices
• Women's uterine health
• Biopolymer drug delivery

Headquarters

HQ city

Montpellier

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

1. Womed Leaf Device Sales: Womed generates revenue through the sale of its Womed Leaf resorbable adhesion barrier, a medical device sold to healthcare providers and through pharmacies. The device is CE marked for the EU and FDA-approved (PMA) for the US market. Distribution occurs through regional medical device distributors and online pharmacies in the EU.
2. Pipeline Product Development: Womed is developing a pipeline of four products targeting intrauterine adhesions, fibroids, acute bleeding, and endometriosis. The company is seeking funding to advance Phase II clinical study for Eynia (fibroid treatment) and accelerate pipeline development for acute bleeding and endometriosis therapies.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels8 records

Core offering

Womed develops and commercializes intrauterine medical devices for women's uterine health, with its flagship Womed Leaf being the first FDA-approved (PMA) and CE-marked resorbable adhesion barrier designed to prevent recurrence of intrauterine adhesions (Asherman syndrome) following hysteroscopic surgery. The product is a 0.02-inch thick polymer film made from PLA and PEO that is inserted through the cervix like an IUD, self-deploys in the uterine cavity, acts as a mechanical barrier for one week, and naturally dissolves. The underlying patented tri-block copolymer platform enables a pipeline of additional products targeting fibroids (Eynia, Phase II), acute uterine bleeding, and endometriosis via targeted low-dose intrauterine drug delivery.

Product overview

Womed is a medtech company developing intrauterine therapies to address women's uterine health conditions including infertility, bleeding, fibroids, and endometriosis. The core product is Womed Leaf, an FDA-approved and CE-marked resorbable adhesion barrier for treating Asherman syndrome. The company's foundational technology is a patented tri-block copolymer platform developed at the University of Montpellier, which enables tunable drug delivery and easy insertion through the cervix. Womed's pipeline includes four products: Womed Leaf (marketed), Eynia for fibroids (Phase II clinical stage), an acute uterine bleeding treatment, and an endometriosis treatment (all in development).

Differentiator

Problem solved

Functional benefit

Brands

• Womed Leaf: FDA-approved resorbable adhesion barrier for treating intrauterine adhesions (Asherman syndrome) following hysteroscopic adhesiolysis. Also known as Womed Leaf®.

Products and services

• Womed Leaf FDA-approved (PMA) and CE-marked resorbable adhesion barrier film that protects the uterine cavity for one week after hysteroscopic surgery, preventing recurrence of intrauterine adhesions (Asherman syndrome). Self-deploys, acts as a mechanical barrier, and naturally discharges without intervention. Intended for use by gynecologists, hysteroscopic surgeons, and fertility specialists treating women with Asherman syndrome and intrauterine adhesions.
• Eynia (Fibroid Treatment) Pipeline product under development using the tri-block copolymer platform for targeted, low-dose intrauterine delivery of a selective progesterone receptor modulator to reduce abnormal bleeding associated with uterine fibroids without surgery or systemic side effects. Currently in Phase II clinical development.
• Acute Uterine Bleeding Treatment Pipeline product under development designed as a rapid treatment to stop acute uterine bleeding in a matter of minutes in emergency suite settings to stabilize patients before diagnosis.
• Endometriosis Treatment Pipeline product under development leveraging the intrauterine drug delivery platform to alleviate pain and suffering associated with endometriosis, helping patients avoid systemic side effects of existing long-term drug therapies.

Quantifiable outcome

• 2.4x higher probability to eliminate adhesions recurrence at second-look hysteroscopy compared to no prevention (41% vs 24% absence of IUA)
• +4 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core and minor.

• KARL STORZcoreChannel Partner/ Reseller/ Distributor · 3 March 2026Strategic distribution partnership under which KARL STORZ serves as the exclusive U.S. distributor of Womed Leaf. This partnership complements KARL STORZ's existing hysteroscopy portfolio while giving Womed access to their established clinical network and customer relationships in the United States. Announced March 2026, marking a major milestone for Womed's global expansion.
• KEBOMEDcoreChannel Partner/ Reseller/ DistributorRegional distributor for Womed Leaf covering France, Germany, Sweden, Denmark, Norway, Finland, Austria, and Switzerland. Healthcare providers can place orders through [email protected].
• Saesco MedicalcoreChannel Partner/ Reseller/ DistributorRegional distributor for Womed Leaf covering Spain, Italy, Portugal, Belgium, Netherlands, and Luxemburg. Orders managed through [email protected].
• HyperpharmaminorChannel Partner/ Reseller/ DistributorEU online pharmacy partner enabling patients with prescriptions to order Womed Leaf directly through hyperpharma.apothical.fr.
• University of MontpelliercoreStrategic or Co-development PartnerWomed originated from research conducted at Pr Garric's biopolymer lab at the University of Montpellier. The research project started in 2013 and Womed SAS was spun off in 2018. Xavier Garric, PhD serves as Scientific Consultant and Director of Polymers for Health and Biomaterials Department at the university.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Femasys: Femasys is a small U.S. medical device company developing and commercializing women's reproductive health products, including intrauterine devices. Like Womed, it targets gynecologists and fertility specialists with novel minimally invasive solutions, and competes for similar patient populations and clinical accounts.
• Gynesonics: Gynesonics develops the Sonata system for intrauterine, transcervical treatment of uterine fibroids — directly overlapping with Womed's Eynia pipeline indication. It is the most directly comparable peer in terms of intrauterine procedural therapy for benign gynecologic conditions.
• Minerva Surgical: Minerva Surgical markets minimally invasive devices for abnormal uterine bleeding, including the Minerva ES endometrial ablation system. It is a comparable women's-health medtech peer focused on intrauterine procedural solutions sold through gynecologic channels.

Broad incumbents

• Hologic: Hologic is a large women's-health medtech incumbent with products spanning diagnostics, breast health, and gynecologic surgery (e.g., NovaSure endometrial ablation, MyoSure tissue removal). It is comparable as a broad competitor and acquirer of intrauterine gynecologic device categories.
• Olympus: Olympus is a leading manufacturer of hysteroscopes and gynecologic surgical instruments. It is comparable as a broad incumbent whose hysteroscopy platform is used during the same procedures where Womed Leaf is inserted, and could in principle develop or distribute competing intrauterine products.
• KARL STORZ: KARL STORZ is a global leader in endoscopy and hysteroscopy systems and Womed's exclusive U.S. distributor. It is comparable both as a channel partner and as a broad incumbent whose installed base of hysteroscopy towers and instruments shapes how Womed Leaf is adopted in clinical practice.
• CooperSurgical: CooperSurgical is a global leader in women's health medical devices and fertility/IVF supplies. As a broad incumbent with a much larger portfolio (including parity products and surgical instruments), it competes with Womed for gynecology accounts and budgets, though it does not have a direct intrauterine adhesion barrier.

Emerging players

• FzioMed: FzioMed develops bioresorbable adhesion barrier products (Oxiplex/AP Gel) used in gynecologic and orthopedic surgery. It is comparable to Womed as a small, specialized adhesion-prevention company targeting post-surgical applications in women's health.
• Anika Therapeutics: Anika Therapeutics markets hyaluronic-acid-based adhesion barrier products (e.g., Hyalobarrier, currently divested in some regions) used in post-surgical adhesion prevention. It is comparable as a niche adhesion-barrier specialist whose technology is adjacent to Womed Leaf's mechanical barrier approach.
• DotLab: DotLab is an early-stage women's health diagnostics company focused on endometriosis — directly overlapping with Womed's endometriosis pipeline indication. It is a comparable emerging peer building a differentiated women's health franchise in adjacent indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=9d6eh2m4_Ho
• Facebookfacebook.com/WOMED-synechie-111017451409034
• LinkedInlinkedin.com/company/womed
• Instagraminstagram.com/womed.synechie

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Womed